Myriad Genetics (NASDAQ:MYGN) Rating Lowered to D+ at TheStreet

Myriad Genetics (NASDAQ:MYGN – Get Rating) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d+” rating in a research note issued on Friday, TheStreetRatingsTable reports. Several other equities research analysts have also recently issued reports on MYGN. The Goldman Sachs Group lowered their price objective on shares of Myriad Genetics […]

Related Keywords

United States ,Danielk Spiegelman , ,Genetics Company Profile Get Rating ,Genetics Inc ,Glenview Capital Management ,Walleye Capital ,Dynamic Technology Lab Private Ltd ,Goldman Sachs Group ,Polar Asset Management Partners Inc ,Myriad Genetics ,Get Rating ,Director Daniel ,Asset Management Partners ,Technology Lab Private Ltd ,Capital Management ,Captrust Financial Advisors ,Financial Advisors ,Genetics Company Profile ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Downgrade ,Thestreet ,